hotspot -WSS

hotspot

author：entertainment 2025-08-26 03:41:39 - browse：2775

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： New study raises questions about niacin and heart health

WSS

Akili changes sales model for its ADHD video game treatment

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Transgender sports debate: Physicians say bans are health issue

Secretariat’s lessons for human medicine

Surprise medical billing ban raises prices elsewhere

The struggle to figure out which patients 'deserve' Wegovy

hotspot

hotspot

leisure time

Hollywood unions extend contract negotiations for actors

Grad students accuse University of California of wage theft

The cancer drug shortage isn’t new — and neither are the solutions

Free Covid tests will again be offered to all U.S. households

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Why the drug industry's warnings on the IRA's impact fall short

The high cost of giving birth even with insurance

PBMs drew scrutiny in House hearing — and so did pharma

Affirmative action in medical school literally saved lives

Medicare Advantage enrollment grows 7.1% to 33.4 million people

hotspot

Congress may force more Covid

Secretariat’s lessons for human medicine

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

FDA panel to weigh safety of artificial wombs for preterm births

Grad students accuse University of California of wage theft

How the messy conversation about Dolly changed bioethics

hotspot

hotspot

hotspot

leisure time